The FDA has approved Monjuvi (tafasitamab-cxix) for use in combination with lenalidomide and rituximab to treat adults with relapsed or refractory follicular lymphoma.

Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

PTCy plus cyclosporine proved more effective than standard GVHD prophylaxis in patients undergoing matched sibling PBSCT in a phase 3 trial.

The program significantly shortens the FDA review time for a sponsor's final drug application submission from approximately 10-12 months to 1-2 months.

Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 ...

An HHS document intended to support the department's change in COVID-19 vaccine policy cites studies that are unpublished or ...

The judge's ruling adds to a growing number of legal decisions halting or scaling back the administration’s actions.

The median overall survival was 19.5 months in the polatuzumab vedotin arm and 12.5 months in the control arm. Adding polatuzumab vedotin to treatment with rituximab, gemcitabine, and oxaliplatin ...

Children with non-germinomatous germ cell tumors may have better IQ recovery if they receive proton radiotherapy rather than photon radiotherapy.

A new SARS-CoV-2 variant, NB.1.8.1, may now account for more than one-third of all COVID-19 cases in the US, health officials say.

Medical school attrition rates are higher among lesbian, gay, and bisexual (LGB) medical students than among their non-LGB peers.

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for certain cancers as well as immunotherapies that are breaking new ground by ...